Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 3
2007 5
2008 1
2009 4
2010 11
2011 3
2012 4
2013 1
2014 1
2016 1
2018 1
2019 3
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Results by year
Filters applied: . Clear all
Page 1
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
Varga A, Soria JC, Hollebecque A, LoRusso P, Bendell J, Huang SA, Wagle MC, Okrah K, Liu L, Murray E, Sanabria-Bohorquez SM, Tagen M, Dokainish H, Mueller L, Burris H. Varga A, et al. Among authors: tagen m. Clin Cancer Res. 2020 Mar 15;26(6):1229-1236. doi: 10.1158/1078-0432.CCR-19-2574. Epub 2019 Dec 17. Clin Cancer Res. 2020. PMID: 31848189 Free article. Clinical Trial.
Anti-chemokine therapy for inflammatory diseases.
Castellani ML, Bhattacharya K, Tagen M, Kempuraj D, Perrella A, De Lutiis M, Boucher W, Conti P, Theoharides TC, Cerulli G, Salini V, Neri G. Castellani ML, et al. Among authors: tagen m. Int J Immunopathol Pharmacol. 2007 Jul-Sep;20(3):447-53. doi: 10.1177/039463200702000303. Int J Immunopathol Pharmacol. 2007. PMID: 17880758 Free article. Review.
A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
Weekes C, Lockhart A, LoRusso P, Murray E, Park E, Tagen M, Singh J, Sarkar I, Mueller L, Dokainish H, Shapiro G, Burris H. Weekes C, et al. Among authors: tagen m. Oncologist. 2020 Oct;25(10):833-e1438. doi: 10.1634/theoncologist.2020-0292. Epub 2020 May 28. Oncologist. 2020. PMID: 32311798 Free PMC article. Clinical Trial.
Chronic fatigue syndrome, mast cells, and tricyclic antidepressants.
Theoharides TC, Papaliodis D, Tagen M, Konstantinidou A, Kempuraj D, Clemons A. Theoharides TC, et al. Among authors: tagen m. J Clin Psychopharmacol. 2005 Dec;25(6):515-20. doi: 10.1097/01.jcp.0000193483.89260.a7. J Clin Psychopharmacol. 2005. PMID: 16282830 No abstract available.
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC. Italiano A, et al. Among authors: tagen m. Ann Oncol. 2018 May 1;29(5):1304-1311. doi: 10.1093/annonc/mdy076. Ann Oncol. 2018. PMID: 29788155 Free article. Clinical Trial.
Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.
McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville MB, Navid F, Santana VM, Houghton PJ, Furman WL, Rodriguez-Galindo C. McGregor LM, et al. Among authors: tagen m. Pediatr Blood Cancer. 2012 Mar;58(3):372-9. doi: 10.1002/pbc.23075. Epub 2011 Apr 20. Pediatr Blood Cancer. 2012. PMID: 21509928 Free PMC article. Clinical Trial.
35 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page